You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Cancers
Submit to Cancers

Cancers, Volume 17, Issue 21

November-1 2025 - 199 articles

Cover Story: Over a decade after its discovery, key advances have clarified the oncogenic role of mutant CALR in BCR::ABL1-negative myeloproliferative neoplasms (MPNs). CALR-mutant disease shows distinct biology, opening opportunities for targeted therapies. Among emerging strategies, immunotherapy is most advanced, with monoclonal antibodies against the CALR neoepitope (e.g., INCA033989) yielding promising hematologic and molecular responses. Other approaches include bispecific antibodies, antibody–drug conjugates, vaccines, and CAR T cells. Preclinical data support bispecific and CAR T-cell efficacy, while vaccination remains limited. Major challenges include monitoring clonal burden, overcoming immune escape, and redefining treatment goals beyond thrombotic risk reduction. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (199)

  • Systematic Review
  • Open Access
571 Views
35 Pages
Download PDF

From Diagnosis to Therapy in Primary Cutaneous Extramammary Paget’s Disease: A Systematic Review of Non-Invasive and Non-Surgical Approaches

  • Francesco D’Oria,
  • Francesco Piscazzi,
  • Matteo Liberi,
  • Giulio Foggi,
  • Luigi Lorini,
  • Katia Maria Calcara,
  • Emi Dika,
  • Mario Valenti,
  • Salvador González and
  • Marco Ardigò
Cancers2025, 17(21), 3594;https://doi.org/10.3390/cancers17213594

6 November 2025

Background/Objectives: Extramammary Paget’s disease (EMPD) is a rare cutaneous malignancy arising in areas rich in apocrine glands that poses diagnostic and therapeutic difficulties. Although surgery remains the standard of care, achieving clea...

Full Article
  • Article
  • Open Access
394 Views
13 Pages
Download PDF

SARIFA Is Associated with Lymph Node Metastases in PT3 and PT4 Gastric Cancers

  • Krešimir Mustapić,
  • Petar Đolonga,
  • Tomislav Ivanović,
  • Ana Paparella Karaman,
  • Luka Minarik,
  • Katarina Vukojević and
  • Merica Glavina Durdov
Cancers2025, 17(21), 3593;https://doi.org/10.3390/cancers17213593

6 November 2025

Background/Objectives: Advanced gastric cancer usually has an unfavorable prognosis. Stroma AReactive Invasion Front Area (SARIFA) is a newly recognized biomarker of aggressiveness, easily recognized as five tumor cells in direct contact with adipocy...

Full Article
  • Article
  • Open Access
335 Views
20 Pages
Download PDF

Divergent Prognostic Value of Primary Tumor Segmentation Metrics on Baseline FDG PET/CT in Colorectal Cancer

  • Ken Kudura,
  • Nando Ritz,
  • Yves Schaulin,
  • Arkadiusz Miszczyszyn,
  • Tim Kutzker,
  • Rebecca Engel,
  • Marco von Strauss und Torney,
  • Wolfgang Harms and
  • Robert Foerster
Cancers2025, 17(21), 3592;https://doi.org/10.3390/cancers17213592

6 November 2025

Background: Colorectal cancer (CRC) remains a major global health concern, with increasing incidence and mortality projected over the coming decades. Despite the central role of staging systems, substantial heterogeneity in clinical outcomes persists...

Full Article
  • Article
  • Open Access
827 Views
13 Pages
Download PDF

The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers

  • Maryam Al-Ani,
  • Bahaaeldin Baraka,
  • Navin Mathiyalagan,
  • Muhammad Adeel Sarwar,
  • Avinash Segaran,
  • Wafaa Abuzahra,
  • Alayna Radford,
  • Kersty Buxton,
  • Lalith Seneviratne and
  • Santhanam Sundar
  • + 6 authors
Cancers2025, 17(21), 3591;https://doi.org/10.3390/cancers17213591

6 November 2025

Background: Pivotal clinical trials have led to the routine clinical use of PARP inhibitor (PARPi) (olaparib, niraparib, or rucaparib) maintenance therapy in high-grade serous tubo-ovarian and peritoneal cancers. Whether various PARPis have comparabl...

Full Article
  • Article
  • Open Access
660 Views
16 Pages
Download PDF

Qualitative Outcomes of Colorectal Cancer Screening Outreach Using Patient Navigation to Follow-Up Colonoscopy in Rural Primary Care Practices

  • Emily Myers,
  • Jennifer Coury,
  • Maryan Carbuccia-Abbott,
  • Amanda F Petrik,
  • Robert Durr,
  • Jamie H Thompson,
  • Erin S Kenzie,
  • Gloria D Coronado and
  • Melinda M Davis
Cancers2025, 17(21), 3590;https://doi.org/10.3390/cancers17213590

6 November 2025

Background/Objectives: Despite its effectiveness, colorectal cancer (CRC) screening rates are suboptimal in the United States. Navigating patients towards complete CRC screening can be effective in addressing barriers. However, to date, much research...

Full Article
  • Review
  • Open Access
710 Views
20 Pages
Download PDF

The Epitranscriptomic Landscape of Gastric Cancer Stem Cells: The Emerging Role of m6A RNA Modifications

  • Diana Pádua,
  • Patrícia Mesquita and
  • Raquel Almeida
Cancers2025, 17(21), 3589;https://doi.org/10.3390/cancers17213589

6 November 2025

Cancer stem cells (CSCs) represent a small but critical subpopulation of tumor cells that drive therapy resistance, relapse and metastasis. Gastric cancer stem cells (GCSCs) have been identified through surface markers and transcriptional signatures,...

Full Article
  • Article
  • Open Access
898 Views
20 Pages
Download PDF

The Role of FGFR3 in the Progression of Bladder Cancer

  • Sahoko Ninomiya,
  • Yukari Ishiguro,
  • Hisashi Hasumi,
  • Ryosuke Jikuya,
  • Akihito Hashizume,
  • Masanobu Yamazaki,
  • Jun-ichi Teranishi,
  • Kazuhide Makiyama,
  • Hiroji Uemura and
  • Hiroshi Miyamoto
  • + 1 author
Cancers2025, 17(21), 3588;https://doi.org/10.3390/cancers17213588

6 November 2025

Introduction: Bladder cancer is associated with a high recurrence rate, and outcomes for muscle-invasive and metastatic disease remain poor. New targeted therapies, such as the FGFR inhibitor erdafitinib, have been introduced, but the progression fro...

Full Article
  • Article
  • Open Access
396 Views
12 Pages
Download PDF

High Implementation Adherence to Lenalidomide in Multiple Myeloma

  • Irina Amitai,
  • Hila Magen,
  • Avi Leader,
  • Antoine Pironet,
  • Eric Tousset,
  • Alon Rozental,
  • Sabina De Geest,
  • Iuliana Vaxman,
  • Pia Raanani and
  • Arnon Nagler
Cancers2025, 17(21), 3587;https://doi.org/10.3390/cancers17213587

6 November 2025

Background and Purpose: Adherence to oral anticancer therapy correlates with outcome. Lenalidomide (LEN) is an oral mainstay treatment for multiple myeloma (MM), administered in 21-day/7-day (on/off) cycles. Data on LEN adherence is limited. Electron...

Full Article
  • Article
  • Open Access
410 Views
11 Pages
Download PDF

Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia

  • Priyatharsini Nirmalanantham,
  • Andrés E. Quesada,
  • Anindita Ghosh,
  • Pei Lin,
  • Chi Y. Ok,
  • Richard K. Yang,
  • Hong Fang,
  • Sofia Garces,
  • Rashmi Kanagal-Shamanna and
  • Sanam Loghavi
  • + 14 authors
Cancers2025, 17(21), 3586;https://doi.org/10.3390/cancers17213586

6 November 2025

Background/Objectives: NOTCH1 is frequently mutated in chronic lymphocytic leukemia (CLL) and is a marker of poor prognosis. In addition to NOTCH1, mutations in the NOTCH1 regulatory pathway including SPEN have been described in a limited number of C...

Full Article
  • Systematic Review
  • Open Access
1,404 Views
21 Pages
Download PDF

A Systematic Review of the Cost-Effectiveness of Screening Modalities for Breast Cancer in European Countries

  • Zacharoula Sidiropoulou and
  • Vasco Fonseca
Cancers2025, 17(21), 3585;https://doi.org/10.3390/cancers17213585

6 November 2025

Background: Breast cancer remains the most diagnosed cancer in European countries, with diverse screening modalities requiring economic evaluation for optimal resource allocation. This systematic review evaluated the cost-effectiveness of breast canc...

Full Article

of 20

Go to next page

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694
Imprint
Download Flyer